StreetInsider.com News Articles

IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026

Mon, 01 Jun 2026 08:30:00 -0400

Repeat dosing of DeltExTM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached).

Results demonstrate the potential for meaningful improvement in outcomes with gamma-delta T cell therapy in combination with the standard-of-care that has remained unchanged for over 20 years.

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and γδ T cell engagers (TCEs) for cancer and

IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026

Mon, 01 Jun 2026 08:30:00 -0400

Repeat dosing of DeltExTM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached).

Results demonstrate the potential for meaningful improvement in outcomes with gamma-delta T cell therapy in combination with the standard-of-care that has remained unchanged for over 20 years.

IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026

Mon, 01 Jun 2026 08:30:00 -0400

Repeat dosing of DeltExTM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached).

Results demonstrate the potential for meaningful improvement in outcomes with gamma-delta T cell therapy in combination with the standard-of-care that has remained unchanged for over 20 years.

IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026

Mon, 01 Jun 2026 08:30:00 -0400

Repeat dosing of DeltExTM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached).

Results demonstrate the potential for meaningful improvement in outcomes with gamma-delta T cell therapy in combination with the standard-of-care that has remained unchanged for over 20 years.

IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026

Mon, 01 Jun 2026 08:30:00 -0400

Repeat dosing of DeltExTM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached).

Results demonstrate the potential for meaningful improvement in outcomes with gamma-delta T cell therapy in combination with the standard-of-care that has remained unchanged for over 20 years.

IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026

Mon, 01 Jun 2026 08:30:00 -0400

Repeat dosing of DeltExTM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached).

Results demonstrate the potential for meaningful improvement in outcomes with gamma-delta T cell therapy in combination with the standard-of-care that has remained unchanged for over 20 years.

IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026

Mon, 01 Jun 2026 08:30:00 -0400

Repeat dosing of DeltExTM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached).

Results demonstrate the potential for meaningful improvement in outcomes with gamma-delta T cell therapy in combination with the standard-of-care that has remained unchanged for over 20 years.

IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026

Mon, 01 Jun 2026 08:30:00 -0400

Repeat dosing of DeltExTM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached).

Results demonstrate the potential for meaningful improvement in outcomes with gamma-delta T cell therapy in combination with the standard-of-care that has remained unchanged for over 20 years.

Form 8-K IN8BIO, INC. For: May 29

Mon, 01 Jun 2026 06:56:00 -0400

si-local-file:///var/storage/secattach/20260601/26578815.html

Form 8-K IN8BIO, INC. For: May 29

Mon, 01 Jun 2026 06:56:00 -0400

si-local-file:///var/storage/secattach/20260601/26578815.html

Form 424B5 IN8BIO, INC.

Mon, 01 Jun 2026 06:17:00 -0400

si-local-file:///var/storage/secattach/20260601/26578552.html

Form 424B5 IN8BIO, INC.

Mon, 01 Jun 2026 06:17:00 -0400

si-local-file:///var/storage/secattach/20260601/26578552.html

Form SCHEDULE 13D/A IN8BIO, INC. Filed by: FAIRBAIRN EMILY

Fri, 29 May 2026 17:41:00 -0400

si-local-file:///var/storage/secattach/20260529/26576784.html

Form SCHEDULE 13D/A IN8BIO, INC. Filed by: FAIRBAIRN EMILY

Fri, 29 May 2026 17:41:00 -0400

si-local-file:///var/storage/secattach/20260529/26576784.html

Form 4 IN8BIO, INC. For: May 27 Filed by: FAIRBAIRN EMILY

Fri, 29 May 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260529/26576782.html

Form 4 IN8BIO, INC. For: May 27 Filed by: FAIRBAIRN EMILY

Fri, 29 May 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260529/26576782.html

Form EFFECT IN8BIO, INC.

Wed, 20 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260520/26524301.html

Form EFFECT IN8BIO, INC.

Wed, 20 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260520/26524301.html

Form S-3/A IN8BIO, INC.

Mon, 18 May 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260518/26515094.html

Form S-3/A IN8BIO, INC.

Mon, 18 May 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260518/26515094.html

IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma

Thu, 14 May 2026 08:00:00 -0400

Multidimensional analyses demonstrate that repeated DeltEx DRI dosing preserves immune function, drives tumor microenvironment remodeling, and correlates with improved survival outcomes in glioblastoma

Translational data combines advanced artificial intelligence (AI), immunogenomics, histopathology, and spatial transcriptomics to provide mechanistic insights into therapeutic response and disease progression

Findings lay the groundwork for rational biomarker discovery, patient stratification, and potential treatment optimization for future DeltEx DRI studies

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and γδ T

IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma

Thu, 14 May 2026 08:00:00 -0400

Findings lay the groundwork for rational biomarker discovery, patient stratification, and potential treatment optimization for future DeltEx DRI studies

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and γδ T

IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma

Thu, 14 May 2026 08:00:00 -0400

Findings lay the groundwork for rational biomarker discovery, patient stratification, and potential treatment optimization for future DeltEx DRI studies

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and γδ T

IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma

Thu, 14 May 2026 08:00:00 -0400

Findings lay the groundwork for rational biomarker discovery, patient stratification, and potential treatment optimization for future DeltEx DRI studies

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and γδ T

IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma

Thu, 14 May 2026 08:00:00 -0400

Findings lay the groundwork for rational biomarker discovery, patient stratification, and potential treatment optimization for future DeltEx DRI studies

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and γδ T